RT Journal Article
SR Electronic
T1 Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.04.22283762
DO 10.1101/2023.01.04.22283762
A1 Horne, Elsie MF
A1 Hulme, William J
A1 Keogh, Ruth H
A1 Palmer, Tom M
A1 Williamson, Elizabeth J
A1 Parker, Edward PK
A1 Walker, Venexia M
A1 Knight, Rochelle
A1 Wei, Yinghui
A1 Taylor, Kurt
A1 Fisher, Louis
A1 Morley, Jessica
A1 Mehrkar, Amir
A1 Dillingham, Iain
A1 Bacon, Sebastien
A1 Goldacre, Ben
A1 Sterne, Jonathan AC
A1 The OpenSAFELY Collaborative
YR 2023
UL http://medrxiv.org/content/early/2023/01/05/2023.01.04.22283762.abstract
AB Quantifying the waning effectiveness of second COVID-19 vaccination beyond six months and against the omicron variant is important for scheduling subsequent doses. With the approval of NHS England, we estimated effectiveness up to one year after second dose, but found that bias in such estimates may be substantial.Competing Interest StatementBG has received research funding from the Bennett Foundation, the Laura and John Arnold Foundation, the NIHR, the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, the Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organization, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he receives personal income from speaking and writing for lay audiences on the misuse of science; he is also a non-executive director of NHS Digital; AM is on the NHS Digital Professional Advisory Group (representing the Royal College of General Practitioners), advising on the use of general practice data for covid-19 related research and planning; until September 2019 he was interim chief medical officer of NHS Digital.Funding StatementThis work was jointly funded by UK Research and Innovation Councils (UKRI; grant numbers COV0076 and MR/V015737/1), the Longitudinal Health and Wellbeing strand of the National Core Studies programme (MC_PC_20030 and MC_PC_20059), the National Institute for Health and Care Research (NIHR) CONVALESCENCE study (COV-LT-0009) and Asthma UK. The OpenSAFELY data science platform is funded by the Wellcome Trust (grant number 222097/Z/20/Z). BG's work on better use of data in healthcare more broadly is currently funded in part by: the Bennett Foundation, the Wellcome Trust, NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation; all Bennett Institute staff are supported by BG's grants on this work. EW holds grants from MRC. RHK was funded by UKRI (Future Leaders Fellowship MR/S017968/1). EPKP was funded by UKRI (COVID-19 data analysis secondment MR/ W021420/1). TMP was supported by the MRC Integrative Epidemiology Unit, which receives funding from the UKRI Medical Research Council and the University of Bristol (MC_UU_00011/1 and MC_UU_00011/3). EH and JACS are funded in part by NIHR135073. JACS is also supported by the NIHR Bristol Biomedical Research Centre and by Health Data Research UK. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, UK Health Security Agency (UKHSA), or the Department of Health and Social Care. The funders had no role in considering the study design or in the collection, analysis, and interpretation of data, writing of the report, or decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Health Research Authority [REC reference 22/PR/0095] and by the University of Bristol's Faculty of Health Sciences Ethics Committee [reference 117269].I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data were linked, stored and analysed securely within the OpenSAFELY platform: https://opensafely.org/. Data include pseudonymised data such as coded diagnoses, medications and physiological parameters. No free text data are included. All code is shared openly for review and re-use under MIT open license https://github.com/opensafely/waning-ve-2dose-1year. Detailed pseudonymised patient data is potentially re-identifiable and therefore not shared. https://github.com/opensafely/waning-ve-2dose-1year